PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide that acts on the brain's melanocortin system rather than on genital blood flow. It carries one FDA approval, granted in 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, while most material sold as PT-141 circulates as a research-use-only gray-market peptide outside that approved pathway.
PT-141 (bremelanotide) is a melanocortin-4 receptor agonist with a single FDA approval, granted in 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, while most PT-141 sold online is unapproved research-use-only material.
Bremelanotide is a seven-amino-acid cyclic peptide that works upstream in the central nervous system, where activation of the melanocortin-4 receptor is believed to engage hypothalamic and limbic circuits tied to sexual desire. That mechanism is what separates it from the PDE5 inhibitors most people know, such as sildenafil, which act peripherally on blood flow and do nothing to generate desire.
Bremelanotide is a synthetic cyclic heptapeptide whose sexual effects are attributed mainly to central melanocortin-4 receptor activation, a neural mechanism distinct from the peripheral, blood-flow action of PDE5 inhibitors such as sildenafil.
PT-141 has exactly one approved indication, and each qualifier in it narrows the population sharply. As Vyleesi, bremelanotide is indicated only for acquired, generalized hypoactive sexual desire disorder in premenopausal women, so postmenopausal women and men fall outside the labeled use even though both use it off label.
Bremelanotide's sole FDA-approved indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women, so all use in men, postmenopausal women, or for erectile complaints is off-label and unstudied at the doses people self-administer.
The approval rested largely on two identically designed phase 3 trials, together the RECONNECT program, which randomized roughly 1,200 premenopausal women with HSDD to on-demand subcutaneous bremelanotide or placebo over 24 weeks. Both the desire score and the associated distress improved significantly versus placebo, but the absolute differences were small and the trials showed no significant rise in satisfying sexual events, the outcome many patients would find most tangible.
| Outcome | Bremelanotide vs placebo | Evidence note |
|---|---|---|
| Sexual desire (FSFI domain) | Statistically significant improvement | Absolute difference small |
| Distress over low desire | Statistically significant improvement | Modest in magnitude |
| Satisfying sexual events | No significant increase | The outcome many patients value most |
| Discontinuation | Substantial dropout | Largely from nausea, not lack of benefit |
In the two phase 3 RECONNECT trials of roughly 1,200 premenopausal women, bremelanotide produced statistically significant but small improvements in sexual desire and related distress over placebo, with no significant increase in satisfying sexual events.
In its approved form, bremelanotide is documented as a single-use subcutaneous autoinjector delivering 1.75 mg into the abdomen or thigh, taken on demand at least 45 minutes before anticipated activity rather than on a daily schedule. The label caps use to limit the transient blood-pressure effect and the risk of skin darkening, while gray-market powder is reconstituted and self-dosed without those manufacturing controls or safeguards.
The approved Vyleesi dose is a single 1.75 mg subcutaneous autoinjection taken at least 45 minutes before anticipated activity, capped by the label at one dose per 24 hours and eight doses per month.
The safety picture is driven by tolerability rather than by catastrophic risk, but it is not trivial. Nausea dominates, reported by roughly 40 percent of women in trials and severe enough to drive a notable share to discontinue, and a distinctive melanocortin effect transiently raises blood pressure for several hours after each dose.
Nausea affects roughly 40 percent of bremelanotide users and is the leading reason for discontinuation, while each dose transiently raises blood pressure, the effect that limits use to one dose per day and rules it out in cardiovascular disease.
The clearest reasons to avoid bremelanotide flow from its cardiovascular effect, and one drug interaction stands out. Because each dose transiently raises blood pressure, the label contraindicates use in uncontrolled hypertension or known cardiovascular disease, and the drug's slowing of gastric emptying can meaningfully reduce absorption of oral naltrexone.
Bremelanotide is contraindicated in uncontrolled hypertension and known cardiovascular disease, is cautioned against with oral naltrexone because it slows gastric emptying and reduces that drug's absorption, and is not recommended in pregnancy or breastfeeding.
Bremelanotide holds a split regulatory identity. As the finished prescription drug Vyleesi it is FDA-approved and legally prescribable within its indication, while the lyophilized powder sold online as PT-141 is an unapproved research chemical labeled not for human use.
As Vyleesi, bremelanotide is an FDA-approved prescription drug cleared in June 2019 and is not a scheduled controlled substance, but the PT-141 powder sold online is unapproved material labeled research-use-only to sidestep drug-approval requirements.
PT-141 occupies a distinct niche because it targets desire through the brain rather than mechanics through the blood vessels. Against PDE5 inhibitors such as sildenafil and tadalafil, which improve the physical capacity for erection but do nothing for libido, it addresses a different complaint entirely, and within the female-desire category its natural comparison is flibanserin, a daily oral pill.
| Criteria | Bremelanotide | Flibanserin |
|---|---|---|
| Dosing | On-demand injection before activity | Daily oral pill |
| Mechanism | Melanocortin (MC4R) agonist | Serotonin and dopamine receptor action |
| Alcohol | No interaction noted | Warned for dangerous hypotension and fainting |
| Main drawback | Nausea, blood-pressure effect, injection | Daily adherence, gradual onset |
Bremelanotide is an on-demand injectable melanocortin agonist for premenopausal HSDD, differing from the daily oral serotonin-dopamine pill flibanserin chiefly in its episodic dosing and its avoidance of flibanserin's alcohol interaction, while both differ from PDE5 inhibitors that treat erectile mechanics rather than desire.
PT-141 traces back to Melanotan II, a melanocortin agonist studied to stimulate skin pigmentation, when subjects and investigators noticed it also produced spontaneous sexual arousal. That observation redirected a pigmentation program toward sexual dysfunction and, roughly two decades later, produced the first FDA-approved on-demand desire drug.
PT-141 originated from the tanning peptide Melanotan II after researchers observed unexpected sexual arousal, was refined by Palatin Technologies and repositioned from a halted intranasal erectile-dysfunction program to a subcutaneous female-desire drug, and reached FDA approval as Vyleesi in 2019, about two decades later.
Educational use only. This article describes what the published scientific and clinical literature reports about PT-141 (bremelanotide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
